Work

Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer

Year: 2025

Type: article

Abstract: Small cell carcinoma of the bladder (SCCB) is a rare and aggressive variant of bladder cancer requiring multimodal treatment. We present a case of an 82-year-old male with SCCB with bulky pelvic adenopathy treated with a novel neoadjuvant combination of carboplatin, etoposide, and durvalumab with complete response of the small cell component. We also describe a rare complication of retinopathy resulting from this treatment. This study presents the potential efficacy and promise of adding immunotherapy to neoadjuvant chemotherapy for SCCB to achieve a long-term cure. • Checkpoint inhibitors as neoadjuvant therapy for small cell bladder cancer (SCCB). • Complete pathologic response in SCCB to durvalumab, cisplatin, and etoposide. • Complication of retinopathy from neoadjuvant carboplatin, etoposide, durvalumab.

Source: Urology Case Reports

DOI: 10.1016/j.eucr.2025.103165

Authors: Victoria Gonzalez, Edward Linton, Timothy Boyce, Laila Dahmoush, Helen Y. Hougen

Institutions: University of Iowa Hospitals and Clinics, University of Iowa Health Care

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,160